| Outcome Measures: |
Primary: Number of treatment emergent adverse events (TEAEs), Count of adverse events, From administration of XW003 on Day 1 to the last follow-up visit | Secondary: Maximum observed XW003 plasma concentration, Calculated based on XW003 measured in blood., 36 days|Time of the maximum observed XW003 plasma concentration, Calculated based on XW003 measured in blood., 36 days|Area under the XW003 plasma concentration-time curve, Calculated based on XW003 measured in blood., 36 days|Apparent terminal half-life of XW003, Calculated based on XW003 measured in blood., 36 days|Apparent terminal elimination rate constant of XW003, Calculated based on XW003 measured in blood., 36 days|Apparent total clearance of XW003, Calculated based on XW003 measured in blood., 36 days|Apparent volume of distribution of XW003, Calculated based on XW003 measured in blood., 36 days|Change from Baseline in body weight, Percentage of body weight loss, Day 36 for Cohort A and Day 71 for Cohort B|Change from Baseline in fasting plasma glucose, Percentage of fasting plasma glucose change, Day 36 for Cohort A and Day 71 for Cohort B|Change from Baseline in plasma insulin and pro-insulin, Percentage of plasma insulin and pro-insulin change, Day 36 for Cohort A and Day 71 for Cohort B|Change from Baseline in plasma C-peptide, Percentage of plasma C-peptide change, Day 36 for Cohort A and Day 71 for Cohort B|Change from Baseline in plasma glucagon, Percentage of plasma glucagon change, Day 36 for Cohort A and Day 71 for Cohort B|Change from Baseline in plasma lipids (triglyceride, low-density lipoprotein [LDL], and high-density lipoprotein [HDL]), Percentage of plasma lipids (triglyceride, low-density lipoprotein \[LDL\], and high-density lipoprotein \[HDL\]) change, Day 36 for Cohort A and Day 71 for Cohort B|Incidence of anti-XW003 antibodies at end of study, Count of episodes, Pre-dose of XW003 on Day 1, end of study visit on Day 36 for Cohort A and Day 71 for Cohort B|Area under the plasma concentration curve time zero to the last detectable time point before second dose, Calculated based on XW003 measured in blood in repeat dose cohorts, 71 days|Area under the plasma concentration curve over a dosing interval after first dosing, Calculated based on XW003 measured in blood in repeat dose cohorts, 71 days|Maximum plasma concentration after first dosing, Calculated based on XW003 measured in blood in repeat dose cohorts, 71 days|Time to maximum plasma concentration after first dosing, Calculated based on XW003 measured in blood in repeat dose cohorts, 71 days|Terminal phase elimination rate-constant after first dosing, Calculated based on XW003 measured in blood in repeat dose cohorts, 71 days|Terminal phase elimination half-life after first dosing, Calculated based on XW003 measured in blood in repeat dose cohorts, 71 days|Clearance after last dosing, Calculated based on XW003 measured in blood in repeat dose cohorts, 71 days|Volume of distribution after last dosing, Calculated based on XW003 measured in blood in repeat dose cohorts, 71 days|AUC accumulation ratio constant, Calculated based on XW003 measured in blood in repeat dose cohorts, 71 days|Trough plasma XW003 concentrations before next dosing (Day 1 to last dosing), Calculated based on XW003 measured in blood in repeat dose cohorts, 71 days
|
